Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. (Q43001526)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

title

Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

liver transplantation

1 reference

1 reference

Valentín Cuervas-Mons

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

E Oton

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

R Barcena

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

J M Moreno-Planas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

A Moreno-Zamora

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

C Barrios

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

S Garcia-Garzon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

A Moreno

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

E Boullosa-Graña

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

E E Rubio-Gonzalez

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M Garcia-Gonzalez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

C Blesa

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

M L Mateos

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

English

0 references

publication date

26 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Transplantation

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

2348-2355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16869810%20AND%20SRC:MED&resulttype=core&format=json

The association between hepatitis C infection and survival after orthotopic liver transplantation

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Prospective study of hepatitis C virus infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Hematologic disorders associated with hepatitis C virus infection and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Outcomes of acute rejection after interferon therapy in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Vascular events associated with alpha interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Hepatic artery stenosis in liver transplanted patients treated with pegylated interferon alpha-2b and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X

Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01470.X